

REMARKS

Claim Amendments

This amendment cancels claims 1-5, 11-12, 15-23 without prejudice. This amendment also adds claims 25-103. With this amendment, claims 6-10, 13-14, 24-103 are in the case. The new claims are supported by the specification and claims as originally filed. New claims 76-89 are supported by the case as filed, including the first original claim 19 and page 4, lines 14-28. New claims 25-37 are supported by the specification as filed on page 5, lines 14-25, and page 5 lines 26 to 30, for example. New claims 38-47 are supported by the specification as filed on page 5 lines 1-12, and page 4, lines 12-14, for example. New claims 48-57 are supported by the specification as filed on page 7, lines 16-18. New claims 58-69 are supported by the specification as filed including claims 11-14, page 6, lines 21-27, and page 7, lines 9-14, for example. New claims 70-75 are supported by the specification as filed on page 6, lines 1-20, for example. New claims 76-83 and 103 are supported by the specification as filed on page 7, lines 15-24, for example. New claims 90-95 are supported by the specification as filed on page 7, lines 9-14, for example. New claims 96-99 are supported by the specification as filed on page 7, lines 21-24, for example. New claims 100 - 103 are supported by the examples in the specification. The new claims are intended to more clearly claim what Applicants regard as the invention. No new matter is added by any new claim.

Restriction Requirement

The Restriction Requirement mailed March 19, 2002 divided the claims into eight groups:

- I: Claims 1-5, drawn to methods of using high affinity TCRs to identify ligands.
- II. Claims 6-10, drawn to methods of using high affinity TCRs as diagnostic probes in vitro or in vivo.
- III. Claim 11, drawn to a method for blocking autoimmune destruction of cells.
- IV. Claim 12, drawn to a method for treating neoplastic disease.
- V. Claims 13-14, drawn to a method for using high affinity TCRs to inactivate pathogens.
- VI. Claims 15-18 and 20, drawn to soluble high affinity TCRs and a library of TCRs

displayed on the surface of yeast cells.

VII. Claim 19, drawn to a DNA library encoding TCRs.

VIII. Claims 21-24, drawn to a method for cloning a gene for a high affinity TCR.


Applicants elect claims corresponding to Group VI, new claims 38 to 57, drawn to soluble high affinity TCRs and T cells expressing high affinity TCRs on their surface, with traverse.

The Restriction Requirement stated the groups were unrelated, and a search of one group would not be co-extensive with a search of the others, and hence would be burdensome. However, all claims in the application are directed to high affinity TCRs, so it is believed a search on the subject matter of the claims would not be burdensome. In addition, several of the Groups have the same classification providing evidence that the same art would be searched.

CONCLUSION

This Preliminary Amendment is accompanied by a check in the amount of \$3,382, which includes \$1,386 for 77 new claims over 20, \$1,596 for 19 independent claims over 3 and \$400 for a 2 month extension of time. If the amount submitted is incorrect, please credit any overpayment or deduct any deficiency, including the fee for any extensions of time due to Deposit Account No. 07-1969.

Respectfully submitted,



Susan K. Doughty
Reg. No. 43,595

GREENLEE, WINNER AND SULLIVAN, P.C.
5370 Manhattan Circle, Suite 201
Boulder, CO 80303
Telephone: (303) 499-8080
Facsimile: (303) 499-8089
E-mail: winner@greenwin.com
Attorney Docket No. 89-99
lfa: June 18, 2002

